Opinion|Videos|May 23, 2025
CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.
Advertisement
Future Directions in HIV Treatment
Key Themes:
- Treatment Evolution: Continuous improvement in HIV medications regarding efficacy, tolerability, and convenience
- Long-Acting Formulations: Development of oral, subcutaneous, intramuscular, and intravenous options
- Combination Products: Future devices potentially combining HIV treatment/prevention with contraception or sexually transmitted infection prevention
- HIV Prevention: New preventive therapies potentially effective for 1 to 2 years
Notable Insights from Dr Sharon Walmsley:
- Long-acting therapies help “demedicalize” HIV by reducing medication frequency.
- New challenges in adherence emerge with transition from daily to weekly or monthly dosing schedules.
- HIV treatment advances have informed approaches to other infectious diseases, including COVID-19 and Mpox.
- Despite prevention advances, questions remain about whether to continue vaccine development efforts given limited success to date.
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5